Safety and Efficacy of HL Tablet in Non-alcoholic Fatty Liver Disease Patients
Status:
Completed
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
This study evaluates the safety and efficacy of HL tablet on reducing hepatic fat in
non-alcoholic fatty liver disease patients. The patients are allocated to three groups; low
dose, high dose, and placebo control group.